The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ribonucleotide reductase subunit-2 (RRM2) and thymidylate synthase (TS) to predict shorter survival in patients (pts) with resected stage I-III non-small cell lung cancer (NSCLC).
Francesco Grossi
No relevant relationships to disclose
Maria Giovanna Dal Bello
No relevant relationships to disclose
Graziana Savarino
No relevant relationships to disclose
Sandra Salvi
No relevant relationships to disclose
Roberto Puzone
No relevant relationships to disclose
Ulrich Pfeffer
No relevant relationships to disclose
Vincenzo Fontana
No relevant relationships to disclose
Erika Rijavec
No relevant relationships to disclose
Giulia Barletta
No relevant relationships to disclose
Carlo Genova
No relevant relationships to disclose
Claudio Sini
No relevant relationships to disclose
Giovanni Battista Ratto
No relevant relationships to disclose
Mauro Truini
No relevant relationships to disclose
Domenico Franco Merlo
No relevant relationships to disclose